ES552368A0 - Un metodo para preparar un hibrido de anticuerpo - Google Patents
Un metodo para preparar un hibrido de anticuerpoInfo
- Publication number
- ES552368A0 ES552368A0 ES552368A ES552368A ES552368A0 ES 552368 A0 ES552368 A0 ES 552368A0 ES 552368 A ES552368 A ES 552368A ES 552368 A ES552368 A ES 552368A ES 552368 A0 ES552368 A0 ES 552368A0
- Authority
- ES
- Spain
- Prior art keywords
- preparing
- antibody hybrid
- antibody
- hybrid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/804—Drug, bio-affecting and body treating compositions involving IgG3, IgG4, IgA, or IgY
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
- Y10S424/807—Monoclonal
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
- Y10S530/864—Monoclonal
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/705,271 US4698420A (en) | 1985-02-25 | 1985-02-25 | Antibody hybrid molecules and process for their preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
ES552368A0 true ES552368A0 (es) | 1987-04-16 |
ES8704734A1 ES8704734A1 (es) | 1987-04-16 |
Family
ID=24832743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES552368A Expired ES8704734A1 (es) | 1985-02-25 | 1986-02-25 | Un metodo para preparar un hibrido de anticuerpo |
Country Status (7)
Country | Link |
---|---|
US (1) | US4698420A (es) |
EP (1) | EP0193161A3 (es) |
JP (1) | JPS61227532A (es) |
AU (1) | AU579058B2 (es) |
CA (1) | CA1239355A (es) |
ES (1) | ES8704734A1 (es) |
NZ (1) | NZ215288A (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5202252A (en) * | 1982-03-05 | 1993-04-13 | Houston Biotechnology Inc. | Monoclonal antibodies against lens epithelial cells and methods for preventing proliferation of remnant lens epithelial cells after extracapsular extraction |
US4863729A (en) * | 1984-06-20 | 1989-09-05 | Linus Pauling Institute Of Science And Medicine | Method for preparing a macromolecular monoclonal antibody composition |
AU587658B2 (en) * | 1985-10-10 | 1989-08-24 | Access Pharmaceuticals Australia Pty Limited | Oral delivery of biologically active substances bound to vitamin b12, or analogues thereof |
US5055561A (en) * | 1985-11-19 | 1991-10-08 | The Johns Hopkins University | Protein label and drug delivery system |
US5616122A (en) * | 1986-11-04 | 1997-04-01 | Baylor College Of Medicine | Methods and compositions for preventing secondary cataracts |
US5055291A (en) * | 1986-11-04 | 1991-10-08 | Baylor College Of Medicine | Compositions for preventing secondary cataracts |
US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
WO1988009344A1 (en) * | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
US5132405A (en) * | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) * | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5447837A (en) * | 1987-08-05 | 1995-09-05 | Calypte, Inc. | Multi-immunoassay diagnostic system for antigens or antibodies or both |
EP0329184A3 (en) * | 1988-02-19 | 1990-05-23 | Neorx Corporation | Antimers and antimeric conjugation |
US5541297A (en) * | 1988-04-01 | 1996-07-30 | Immunomedics, Inc. | Therapeutic conjugates of toxins and drugs |
US5171563A (en) * | 1988-09-30 | 1992-12-15 | Neorx Corporation | Cleavable linkers for the reduction of non-target organ retention of immunoconjugates |
WO1990003188A1 (en) * | 1988-09-30 | 1990-04-05 | Neorx Corporation | Cleavable linkers for the reduction of non-target organ retention of immunoconjugates |
DE69130561T2 (de) * | 1990-02-16 | 1999-06-24 | Boston Biomed Res Inst | Hybride Reagenzien mit der Fähigkeit, Moleküle selektiv in Zellen freizusetzen |
US5185433A (en) * | 1990-04-09 | 1993-02-09 | Centocor, Inc. | Cross-linking protein compositions having two or more identical binding sites |
US5212075A (en) * | 1991-04-15 | 1993-05-18 | The Regents Of The University Of California | Compositions and methods for introducing effectors to pathogens and cells |
US5364612A (en) * | 1991-05-06 | 1994-11-15 | Immunomedics, Inc. | Detection of cardiovascular lesions |
US6248564B1 (en) * | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
US20030035798A1 (en) * | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
EP1270596A4 (en) * | 2000-04-07 | 2003-06-04 | Matsushita Electric Ind Co Ltd | ANTIBODY-CARRIER COMPLEX, METHOD OF ITS PRODUCTION, METHOD FOR CONTROLLING ANTIQUE-ANTIBODY REACTION BY USING THE COMPLEX AND IMMUNASSAY METHOD |
CA2454358A1 (en) | 2001-07-19 | 2003-07-31 | Perlan Therapeutics, Inc. | Multimeric proteins and methods of making and using same |
SE0201655D0 (sv) * | 2002-05-31 | 2002-05-31 | Amersham Biosciences Ab | A method of electrophoresis |
WO2009026274A1 (en) | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
KR20100107501A (ko) * | 2008-01-18 | 2010-10-05 | 메디뮨 엘엘씨 | 부위 특이적 접합을 위한 시스테인 조작 항체 |
EA028336B1 (ru) | 2009-03-05 | 2017-11-30 | МЕДАРЕКС Л.Л.Си. | Полностью человеческие антитела, специфические в отношении cadm1 |
EP2270506A3 (en) * | 2009-07-02 | 2011-03-09 | Amic AB | Amplified labeled conjugate for use in immunoassays |
US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
EP2814829B1 (en) | 2012-02-13 | 2016-12-07 | Bristol-Myers Squibb Company | Enediyne compounds, conjugates thereof, and uses and methods therefor |
KR102215954B1 (ko) | 2013-02-14 | 2021-02-15 | 브리스톨-마이어스 스큅 컴퍼니 | 튜부리신 화합물, 그의 제조 및 사용 방법 |
US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
ES2747386T3 (es) | 2015-01-14 | 2020-03-10 | Bristol Myers Squibb Co | Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso |
KR102493853B1 (ko) | 2016-08-19 | 2023-01-30 | 브리스톨-마이어스 스큅 컴퍼니 | 세코-시클로프로파피롤로인돌 화합물, 그의 항체-약물 접합체, 및 제조 및 사용 방법 |
WO2018075842A1 (en) | 2016-10-20 | 2018-04-26 | Bristol-Myers Squibb Company | Condensed benzodiazepine derivatives and conjugates made therefrom |
US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
US11485741B2 (en) | 2018-04-24 | 2022-11-01 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (TLR7) agonists |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
CN114137203A (zh) * | 2021-10-21 | 2022-03-04 | 广州万孚生物技术股份有限公司 | 抗原与碱性磷酸酶结合物的制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3903262A (en) * | 1972-03-13 | 1975-09-02 | Cutter Lab | Pharmaceutical compositions comprising intravenously injectable modified serum globulin, its production and use |
FR2437213A1 (fr) * | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
JPS5616418A (en) * | 1979-07-20 | 1981-02-17 | Teijin Ltd | Antitumor protein complex and its preparation |
JPS5686121A (en) * | 1979-12-14 | 1981-07-13 | Teijin Ltd | Antitumor proten complex and its preparation |
US4359457A (en) * | 1980-09-30 | 1982-11-16 | Neville Jr David M | Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant |
US4350236A (en) * | 1980-12-08 | 1982-09-21 | Ford Aerospace & Communications Corp. | Electromagnetic clutch assembly |
JPS57106626A (en) * | 1980-12-22 | 1982-07-02 | Teijin Ltd | Cytotoxic protein complex and its preparation |
US4489710A (en) * | 1981-06-23 | 1984-12-25 | Xoma Corporation | Composition and method for transplantation therapy |
FR2516794B1 (fr) * | 1981-11-20 | 1985-10-25 | Sanofi Sa | Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique |
US4520226A (en) * | 1982-07-19 | 1985-05-28 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates |
JPS59116229A (ja) * | 1982-12-24 | 1984-07-05 | Teijin Ltd | 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法 |
SE8302758L (sv) * | 1983-05-17 | 1984-11-18 | Pharmacia Ab | Sett for uppspjelkning av disulfidbindningar och derigenom erhallen forening |
EP0146050B1 (en) * | 1983-12-16 | 1990-07-04 | Denis M. Callewaert | Site selective plasminogen activator and method of making and using same |
-
1985
- 1985-02-25 US US06/705,271 patent/US4698420A/en not_active Expired - Fee Related
-
1986
- 1986-02-24 CA CA000502534A patent/CA1239355A/en not_active Expired
- 1986-02-25 ES ES552368A patent/ES8704734A1/es not_active Expired
- 1986-02-25 NZ NZ215288A patent/NZ215288A/xx unknown
- 1986-02-25 JP JP61040134A patent/JPS61227532A/ja active Pending
- 1986-02-25 EP EP86102407A patent/EP0193161A3/en not_active Withdrawn
- 1986-02-25 AU AU54027/86A patent/AU579058B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
NZ215288A (en) | 1989-08-29 |
EP0193161A3 (en) | 1988-09-14 |
AU579058B2 (en) | 1988-11-10 |
ES8704734A1 (es) | 1987-04-16 |
AU5402786A (en) | 1986-08-28 |
CA1239355A (en) | 1988-07-19 |
JPS61227532A (ja) | 1986-10-09 |
US4698420A (en) | 1987-10-06 |
EP0193161A2 (en) | 1986-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES552368A0 (es) | Un metodo para preparar un hibrido de anticuerpo | |
ES547326A0 (es) | Un metodo para preparar esterol-liposomas | |
ES554969A0 (es) | Un procedimiento para preparar un complejo de inmunogeno | |
ES544968A0 (es) | Un metodo para preparar un gel de silice-titania | |
ES549633A0 (es) | Un metodo para preparar un sistema de anticuerpo inmoviliza-do | |
ES557006A0 (es) | Un metodo para preparar 6-hidroxi-2-acetilnaftaleno | |
ES557182A0 (es) | Un metodo para preparar derivados de cefem | |
ES545386A0 (es) | Un procedimiento para preparar un organotitanato | |
ES523419A0 (es) | Un metodo para preparar derivados de 4-hidroxi-2-quinolona | |
ES551064A0 (es) | Un metodo para preparar derivados de cefem | |
ES554206A0 (es) | Un metodo para producir anticuerpos monoclonales | |
ES554810A0 (es) | Un metodo para producir un ester alcanoato. | |
ES530016A0 (es) | Un metodo para preparar derivados de 3-metilflavona | |
ES544862A0 (es) | Un metodo para preparar un compuesto de morfolinol | |
ES557082A0 (es) | Un procedimiento para producir un anticuerpo monoclonal | |
ES550467A0 (es) | Un metodo para preparar derivados de 9-bencilpurina | |
ES535381A0 (es) | Un metodo para preparar un derivado de azuleno | |
ES546530A0 (es) | Un procedimiento para preparar un polipeptido hibrido. | |
ES529181A0 (es) | Un procedimiento para preparar un unguento oleoso a base de butirato-propionato de hidrocortisona | |
ES534354A0 (es) | Un metodo para preparar derivados de fenotiazina | |
ES555741A0 (es) | Un metodo para producir anticuerpos monoclonales humanos | |
ES552846A0 (es) | Un metodo para producir interleuquina-2 | |
AR241134A1 (es) | Un procedimiento para preparar w-lactamas | |
ES557568A0 (es) | Un procedimiento para preparar etil-alfa-(1-carboxi-etil)-ami-no-gamma-fenilbutirato | |
ES551424A0 (es) | Un metodo para producir un interferon-gamma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD1A | Patent lapsed |
Effective date: 19970203 |